Return on Innovation: A Three-Part Series

cro_thumnail_2.jpgTo become more efficient in research and development and maximize their returns on approved therapies, pharmaceutical companies are outsourcing more functional areas. That’s creating opportunities for strategic buyers and private equity investors.

In this article series, Paul Hepper, a managing director in the Harris Williams Healthcare & Life Sciences Group, discusses the specific areas within outsourced pharmaceutical services offering buyer upside—and the strategies that can unlock potential.